Collegeville, PA, United States of America

Beata Holkova

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Springworks Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Beata Holkova. Retrieved from https://idiyas.com/inventor/beata-holkova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Beata Holkova - Innovator in Cancer Treatment

Introduction

Beata Holkova is an accomplished inventor based in Collegeville, PA (US). She has made significant contributions to the field of cancer treatment, particularly in the development of innovative therapies. Although she currently holds no granted patents, her work is noteworthy for its potential impact on medical science.

Latest Patent Applications

Beata Holkova's latest patent application is titled "Combination Therapy with an Anti BCMA Antibody and a Gamma Secretase Inhibitor." This application discloses a method for treating cancer, specifically multiple myeloma, through the combination of an anti-BCMA (B cell maturation antigen) antibody, Belantamab mafodotin (GSK2857916), and a gamma-secretase inhibitor, such as nirogacestat (PF03084014). The application also details dosages, treatment duration, and the timing of administration between the two therapeutic agents.

Conclusion

Beata Holkova's innovative approach to cancer treatment highlights her dedication to advancing medical therapies. Her work in combination therapies may pave the way for more effective treatments in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…